Table 2.

Comparison of immunotherapy strategies for multiple myeloma.

	Antibody-Drug Conjugate(s)	Bispecific Antibodies	CAR-T
Pros	“Off the shelf“ product	“Off the shelf” product	High response in the relapsed refractory setting
	Independent from host immune function	High response in the relapsed refractory setting	Only one treatment required
	No delay in administration	No delay in administration
	Can be given in the community setting	Can be given in the community setting?
Cons	High cost	High cost	High cost
	Continuous therapy	Continuous therapy	Long production time (4–6 weeks)
	Higher doses may be required for antigen downmodulation	CRS and ICANs toxicity	CRS and ICANs toxicity
	Payload mediated toxicity		Requires conditioning therapy
	Potential lower response rate		Require adequate lymphocyte count and function

CRS: Cytokine release syndrome. ICANs: immune effector cell associated neurotoxicity syndrome.